The DOI matches its Crossref record.
EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics
Abstract
Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play critical roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis. Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines. In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers. Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature. Thus, EphA2 receptors are attractive targets for drug design, as targeting these molecules could simultaneously inhibit several aspects of tumor progression. This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clinical results of EphA2 inhibition in various cancer model systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Eph-Ephrin Bidirectional Signaling in Physiology and Disease
Pasquale, E. B. (2008) · Cell · doi:10.1016/j.cell.2008.03.011 · Cited by 1,252
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Miao, H., Li, D.-Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J. P., Sedor, J., Wu, J., Danielpour, D., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.009 · Cited by 533
Brantley-Sieders, D. M., Zhuang, G., Hicks, D., Fang, W. B., Hwang, Y., Cates, J. M. M., Coffman, K., Jackson, D., Bruckheimer, E., Muraoka-Cook, R. S., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33154 · Cited by 278
Self-citationNovel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Wang, S., Placzek, W. J., Stebbins, J. L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E. B., & Pellecchia, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201743s · Cited by 94
Metadata
- Authors
- Ireton, R., & Chen, J.
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-05-01
- Volume
- 5
- Issue
- 3
- Pages
- 149-157
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2049547244
- Cited by
- 178
- References
- 0
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics. https://app.cochat.ai/papers/10.2174/1568009053765780
- The paper
- Ireton, R., & Chen, J. (2005). EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics. Current Cancer Drug Targets. https://doi.org/10.2174/1568009053765780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.